|
Post by mnkdmorelong on Jan 12, 2016 20:47:33 GMT -5
In his responses to comments. Got it! George is pissed!
|
|
|
Post by oldfishtowner on Jan 12, 2016 22:41:53 GMT -5
Obviously I don't know if the 35% number Rho quoted and Sanofi gave out is accurate or not. I think it is notable that Rho did not question it. It's also higher than what I've heard some shorts proclaim it was (though it is clearly lower than what those on the long side believe). The fact that it splits the difference makes me think it is not an outlandish number. Regarding the reporting of the LA Times, this is the same newspaper that has regularly treated Al Mann as a local hero for the last few years and has given considerable positive press to Al, Mannkind, and Afrezza. I don't believe it suddenly turned on a dime so as to now start indiscriminately reporting made up negative and / or negatively slanted numbers. YMMV. Yes the Times has turned. Compare the Jan 6 article by Koren www.latimes.com/business/la-fi-mannkind-sanofi-20160106-story.html with his Jan 8 article www.latimes.com/business/la-fi-afrezza-patients-20160108-story.html where the literal bottom line is a quote from a pharmaceutical economist: “I don’t think most people, including Sanofi, see inhaled insulin as fitting a really important need at this point, particularly with these new diabetes drugs.” The new drugs that solve diabetics problems and are taking the market away from Afrezza are the SGLT2 inhibitors. Then yesterday's Times article by Peterson www.latimes.com/business/la-fi-mannkind-ceo-20160111-story.html states bluntly that "Afrezza has been difficult to sell because of its safety risks." Koren's first article correctly laid the blame for tepid sales on Sanofi. And how can the Times say there is a safety concern with Afrezza and SGLT2 inhibitors are going to eat Afrezza's lunch when a cursory look at the labels would show there is much more to be concerned about with the SGLT2's than Afrezza. For starters SGLT2's clearly increase the risk of hypos - it says so on the label - while everyone knows Afrezza lowers the risk of hypos. That alone should weigh in favor of Afrezza. I am leaning in George Rhos direction that there is a conspiracy against MNKD and Afrezza. I don't think you can chalk up the Times' shift in attitude toward MNKD and Afrezza to just sloppy reporting. It's more likely these stories are being placed by those out to crush MNKD and Afrezza. There is just too much inaccurate and plain false information being circulated.
|
|